Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.44 |
| ▸ | HTR2C | P28335 | 15/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14224494 | 0.86 | HTR2A (0.38) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL18959352 | 0.86 | HTR2A (0.38) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL8255348 | 0.86 | HTR2A (0.38) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL13860755 | 0.80 | HTR2A (0.32) | HTR2AHTR2C | |
| SCHEMBL2600365 | 0.79 | HRH3 (0.36) | MEN1KMT2AALDH1A1 | |
| SCHEMBL20932728 | 0.79 | — | — | |
| SCHEMBL18458215 | 0.79 | ADH1B (0.32) | — | |
| SCHEMBL13397343 | 0.79 | — | — | |
| SCHEMBL24723678 | 0.79 | HTR2A (0.40) | HTR2AHTR2CL3MBTL1MEN1KMT2A | |
| SCHEMBL13315452 | 0.78 | HTR2A (0.41) | HTR2AHTR2CL3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023089052-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2023-05-25 | — | — | WO | disclosed |
| US-11542240-B2 | STK19 inhibitors for treatment of cancer | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| WO-2022006550-A1 | 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TREATMENT OF PROLIFERATIVE DISEASES | REMIX THERAPEUTICS INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-04-15 | — | — | US | disclosed |
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20200231590-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-23 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-7223785-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-05-24 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7169784-B2 | Medical devices employing triazine compounds and compositions thereof | REDDY US THERAPEUTICS, INC. (US) | 2007-01-30 | — | — | US | disclosed |
| US-7163943-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-01-16 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. | 2007-01-04 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | HTR2A 1682/4885HTR2C 1976/4885L3MBTL1 456/4885 |
| US-20070004729-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | HTR2A 1479/4885HTR2C 1931/4885L3MBTL1 4810/4885 |
| US-10851102-B2 | Imidazole and triazole containing bicyclic compounds as JAK inhibitors | JAK3, JAK1, JAK2 | HTR2A 3512/4885HTR2C 1062/4885L3MBTL1 4453/4885 |
| US-20070117758-A1 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | METAP2, METAP1, ADM2 | HTR2A 2659/4885HTR2C 3727/4885L3MBTL1 3399/4885 |
| US-20230192645-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | HTR2A 1544/4885HTR2C 1098/4885L3MBTL1 3589/4885 |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | HTR2A 3682/4885HTR2C 1365/4885L3MBTL1 4649/4885 |
| US-11542240-B2 | STK19 inhibitors for treatment of cancer | STK11, CDK9, STK3 | HTR2A 4750/4885HTR2C 4839/4885L3MBTL1 2292/4885 |
| US-20210107891-A1 | INDOLE CARBOXAMIDE COMPOUNDS | BTK, JAK2, BRD4 | HTR2A 1544/4885HTR2C 1098/4885L3MBTL1 3589/4885 |
| US-20200231590-A1 | IMIDAZOLE AND TRIAZOLE CONTAINING BICYCLIC COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | HTR2A 3512/4885HTR2C 1062/4885L3MBTL1 4453/4885 |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | HTR2A 734/4885HTR2C 848/4885L3MBTL1 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.